Glutamate, brain connectivity and duration of untreated psychosis
Glutamate, brain connectivity and duration of untreated psychosis
批准号:
9199583
负责人:
ADRIENNE C LAHTI
金额:
$55.94万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2019-01-31
关键词:
AffectAftercareAntipsychotic AgentsAstrocytesAttenuatedAutopsyBiological MarkersBrainBrain imagingBrain regionChronic DiseaseClinicalDataDeteriorationDiffusion Magnetic Resonance ImagingDiseaseEnrollmentExposure toFunctional Magnetic Resonance ImagingFunctional disorderGlutamatesGlutamineInterventionLeadMagnetic Resonance SpectroscopyMeasuresMeta-AnalysisMonitorMyelinN-Methyl-D-Aspartate ReceptorsN-acetylaspartateNeurobiologyNeuronal PlasticityNeuronsOligodendrogliaOutcomePathologicPatientsPharmaceutical PreparationsPhaseProtonsPsychotic DisordersRecoveryReportingRestRisperidoneScanningSchizophreniaSuggestionSynaptic TransmissionSystemTechniquesTestingTimeTreatment outcomecognitive abilityfirst episode psychosishigh riskindexingmultimodalityneuroimagingpublic health relevancerelating to nervous systemresponsesocialsymptom treatmenttraffickingtreatment effecttreatment responsewhite matter
中文摘要
描述(由申请人提供):精神分裂症的前驱期和早期阶段与社会和智力能力的显著下降有关,慢性疾病的下降程度更轻。荟萃分析一致确定了未经治疗的精神病(DUP)的持续时间较长,阳性症状发作和治疗之间的持续时间,以及长期结局较差之间的关系。然而,这种现象的神经生物学及其对抗精神病药物反应的影响仍然知之甚少。 谷氨酸能过量改变大脑连接可能为为什么DUP时间较长的人临床结果较差提供了解释。我们建议使用多模式神经影像学研究67例首次发作的精神病受试者治疗前和治疗后16周与利培酮,一种常用的处方抗精神病药。我们将测量(1)谷氨酸和(2)结构和功能性脑连接的指数,并测试以下假设:首次发作患者中存在谷氨酸能异常,并且较长的DUP与更大的功能和结构连接异常相关,这些异常为治疗反应不良奠定了基础。 我们以前的联合磁共振波谱(1H-MRS),扩散张量成像(DTI),静息状态功能磁共振成像(fMRI)的研究取得了进展,在了解异常的谷氨酸系统和大脑连接的未服药的精神分裂症患者和调制这些抗精神病药物。我们已经确定了两个指标的谷氨酸能功能障碍,谷氨酸升高和干扰N-乙酰天冬氨酸和谷氨酸之间的已知相关性,这是谷氨酸/谷氨酰胺循环异常的提示。虽然抗精神病药物似乎可以调节谷氨酸,但代谢物之间相关性的紊乱不会随着治疗而恢复。此外,我们发现,未用药的精神分裂症患者的结构和功能连接异常预测患者随后对治疗的反应。 据我们所知,没有其他小组进行了一项研究,使用互补的神经影像学技术的组合,将允许产生一个广泛的表征脑功能和大脑连接在首发精神病和他们的变化与治疗。拟议研究的结果可能表明DUP与不良治疗反应相关的机制,这可能导致针对DUP的新干预措施。
英文摘要
DESCRIPTION (provided by applicant): The prodromal phase and the early stages of the schizophrenia illness are associated with significant decreases in social and intellectual abilitie, with more modest declines seen with chronic disease. Meta-analyses have consistently identified a relationship between the longer duration of untreated psychosis (DUP), the duration between the onset of positive symptoms and treatment, and worse long term outcomes. However, the neurobiology of this phenomenon and its implications for response to antipsychotic medications remain poorly understood. Glutamatergic excess altering brain connectivity might provide an explanation for why those with longer DUP have worse clinical outcomes. We propose to use multimodal neuroimaging to study 67 first episode psychosis subjects before and after sixteen weeks of treatment with risperidone, a commonly prescribed antipsychotic. We will measure indices of (1) glutamate and (2) structural and functional brain connectivity and test the hypotheses that glutamatergic abnormalities are present in first episode patients and that longer DUP is associated with greater functional and structural connectivity abnormalities that set the stage for poor response to treatment. Our previous combined MR spectroscopy (1H-MRS), diffusion tensor imaging (DTI), and resting state functional MR (fMRI) studies have made progress in the understanding of abnormalities in the glutamate system and brain connectivity in unmedicated patients with schizophrenia and modulation of these by antipsychotic medication. We have identified two indices of glutamatergic dysfunction, elevated glutamate and a disturbance in the known correlation between N-acetyl-aspartate and glutamate, which is suggestive of glutamate/glutamine cycle abnormalities. While antipsychotic medications appear to modulate glutamate, the disturbance in the correlation between metabolites is not restored with treatment. In addition, we found that both structural and functional connectivity abnormalities in unmedicated patients with schizophrenia predict patients' subsequent response to treatment. To our knowledge, no other group has performed a study that uses a combination of complementary neuroimaging techniques that will allow generating a broad characterization of glutamatergic function and brain connectivity in first episode psychosis and their change with treatment. The results of proposed studies could suggest a mechanism by which DUP is associated with poor treatment response which might lead to new interventions to target DUP.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Trajectories of treatment response as window into the heterogeneity of psychosis: a longitudinal multimodal imaging study in medication-naieve first episode psychosis patients
-
批准号:10318973
-
项目类别:
-
资助金额:$80.55万
-
财政年份:2018
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Glutamate, brain connectivity and duration of untreated psychosis
-
批准号:8996064
-
项目类别:
-
资助金额:$55.94万
-
财政年份:2014
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Glutamate, brain connectivity and duration of untreated psychosis
-
批准号:8652734
-
项目类别:
-
资助金额:$63.18万
-
财政年份:2014
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Treatment response in schizophrenia: bridging imaging and postmortem studies
-
批准号:8369333
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2008
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Treatment response in schizophrenia: bridging imaging and postmortem studies
-
批准号:7580761
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2008
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Treatment response in schizophrenia: bridging imaging and postmortem studies
-
批准号:7740847
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2008
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Treatment response in schizophrenia: bridging imaging and postmortem studies
-
批准号:7991340
-
项目类别:
-
资助金额:$35.89万
-
财政年份:2008
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Treatment response in schizophrenia: bridging imaging and postmortem studies
-
批准号:8197442
-
项目类别:
-
资助金额:$35.89万
-
财政年份:2008
-
负责人:ADRIENNE C LAHTI
-
依托单位:
3P8WKCIOZ
-
批准号:7203281
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2005
-
负责人:ADRIENNE C LAHTI
-
依托单位:
CEREBRAL BLOOD FLOW (CBF) & CEREBRAL ELECTRICAL ACTIVITY DURING BEHAVIORAL TASKS
-
批准号:7203315
-
项目类别:
-
资助金额:$0.3万
-
财政年份:2005
-
负责人:ADRIENNE C LAHTI
-
依托单位:
Cerebral Blood Flow/Electrical Activity--Behavior Tasks
-
批准号:6981307
-
项目类别:
-
资助金额:$1.88万
-
财政年份:2004
-
负责人:ADRIENNE C LAHTI
-
依托单位:
(S)-3-3(3-Hydroxphyenl)-N Propylpiperdine Hydrochloride
-
批准号:6981309
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2004
-
负责人:ADRIENNE C LAHTI
-
依托单位:
BLOOD FLOW CHANGES AND ANTIPSYCHOTIC DRUG ACTION
-
批准号:6351728
-
项目类别:
-
资助金额:$27.89万
-
财政年份:1999
-
负责人:ADRIENNE C LAHTI
-
依托单位:
BLOOD FLOW CHANGES AND ANTIPSYCHOTIC DRUG ACTION
-
批准号:6151489
-
项目类别:
-
资助金额:$27.08万
-
财政年份:1999
-
负责人:ADRIENNE C LAHTI
-
依托单位:
BLOOD FLOW CHANGES AND ANTIPSYCHOTIC DRUG ACTION
-
批准号:6499270
-
项目类别:
-
资助金额:$28.69万
-
财政年份:1999
-
负责人:ADRIENNE C LAHTI
-
依托单位:
BLOOD FLOW CHANGES AND ANTIPSYCHOTIC DRUG ACTION
-
批准号:2851853
-
项目类别:
-
资助金额:$27.51万
-
财政年份:1999
-
负责人:ADRIENNE C LAHTI
-
依托单位:
海外基金